全文获取类型
收费全文 | 2245篇 |
免费 | 199篇 |
国内免费 | 68篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 90篇 |
妇产科学 | 30篇 |
基础医学 | 295篇 |
口腔科学 | 82篇 |
临床医学 | 275篇 |
内科学 | 429篇 |
皮肤病学 | 49篇 |
神经病学 | 149篇 |
特种医学 | 294篇 |
外科学 | 237篇 |
综合类 | 59篇 |
一般理论 | 1篇 |
预防医学 | 254篇 |
眼科学 | 28篇 |
药学 | 153篇 |
中国医学 | 1篇 |
肿瘤学 | 80篇 |
出版年
2021年 | 31篇 |
2020年 | 19篇 |
2019年 | 31篇 |
2018年 | 41篇 |
2017年 | 29篇 |
2016年 | 32篇 |
2015年 | 44篇 |
2014年 | 57篇 |
2013年 | 64篇 |
2012年 | 61篇 |
2011年 | 67篇 |
2010年 | 75篇 |
2009年 | 79篇 |
2008年 | 79篇 |
2007年 | 107篇 |
2006年 | 82篇 |
2005年 | 71篇 |
2004年 | 59篇 |
2003年 | 48篇 |
2002年 | 55篇 |
2001年 | 50篇 |
2000年 | 61篇 |
1999年 | 58篇 |
1998年 | 80篇 |
1997年 | 90篇 |
1996年 | 87篇 |
1995年 | 81篇 |
1994年 | 53篇 |
1993年 | 66篇 |
1992年 | 47篇 |
1991年 | 51篇 |
1990年 | 37篇 |
1989年 | 74篇 |
1988年 | 49篇 |
1987年 | 64篇 |
1986年 | 34篇 |
1985年 | 50篇 |
1984年 | 36篇 |
1983年 | 42篇 |
1982年 | 25篇 |
1981年 | 31篇 |
1980年 | 26篇 |
1979年 | 19篇 |
1978年 | 22篇 |
1977年 | 18篇 |
1975年 | 18篇 |
1971年 | 12篇 |
1970年 | 9篇 |
1967年 | 9篇 |
1966年 | 10篇 |
排序方式: 共有2512条查询结果,搜索用时 15 毫秒
51.
David K. Ornstein Ganesh S. Rao Brooke Johnson Elaine T. Charlton Gerald L. Andriole 《Urology》1996,48(6):901-905
Objectives
To evaluate the efficacy of combined finasteride and flutamide therapy in men with advanced prostate cancer by determining (1 ) the short-term tolerability of finasteride monotherapy and its effect on serum prostate-specific antigen (PSA) and hormone (testosterone, dihydrotestosterone) levels, and (2) the effects of the addition of flutamide on tolerability and on serum PSA and hormone levels.Methods
Thirteen hormone-naive men with advanced prostate cancer (4 with Stage D2, 1 with Stage D1, 1 with Stage DO, 7 with rising PSA levels after radical prostatectomy [n = 2]or definitive radiation therapy [n = 5]) were initially treated with 5 mg finasteride daily. Flutamide (250 mg three times a day) was added after serum PSA levels stabilized.Results
Finasteride alone (median 5 weeks) had no significant effect on serum PSA levels (P>0.05). Combined finasteride and flutamide resulted in a mean 91% reduction in serum PSA levels, with 85% of men achieving a nadir serum PSA level of less than 4.0 ng/mL and 46% achieving undetectable levels (0.2 ng/mL or less). Finasteride alone had no significant effect on serum testosterone levels (P>0.05) but did result in a mean 74% reduction in serum dihydrotestosterone levels. Combined finasteride and flutamide resulted in a mean 56% increase in serum testosterone levels but had no additional effect on serum dihydrotestosterone levels (P>0.05). Side effects occurred in 85% (gynecomastia or breast tenderness in 62% [8 of 13]and diarrhea in 23% [3 of 13]) of men on combined therapy. Potency was preserved in 66%. Combined finasteride and flutamide therapy was withdrawn from 15% (2 of 13) because of flutamide-induced diarrhea and from 23% (3 of 13) because of disease progression. All remaining patients (8 of 13) have serum PSA levels below 4.0 ng/mL and 4 of these 8 have undetectable levels. These men have received combined finasteride and flutamide for a median 11 months (range 6 to 19).Conclusions
Finasteride monotherapy is inadequate therapy for advanced prostate cancer, but combined finasteride and flutamide may be a reasonable alternative for men with advanced prostate cancer who refuse conventional hormone therapy. 相似文献52.
53.
Objective: To evaluate the incidence and severity of apnoea and bradycardia in hospitalized preterm infants following immunization at 2 months of age, and identify risk factors.
Methodology: A prospective study of 98 preterm infants, of gestational age 24–31 weeks, immunized at approximately 2 months post natal age with diphtheria-tetanus-whole cell pertussis vaccine (DTPw ) in the neonatal intensive care unit (NICU) at King George V Hospital Sydney. Half the infants also received Haemophilus influenzae type b conjugate vaccine (Hib) simultaneously. All infants were monitored for apnoea and bradycardia in the 24 h periods pre- and post immunization.
Results: Only one infant had apnoea and/or bradycardia pre-immunization compared with 17 post immunization. For 12 infants these events were brief, self-limiting and not associated with desaturations (oxygen saturation <90%). However, for five infants (30%) these events were associated with oxygen desaturation and two of these infants required supplemental oxygen. The group that had apnoea and/or bradycardia and the group that did not were not significantly different in terms of gestational age, birth weight and other variables. Infants who received Hib together with DTPw were less likely to have apnoea and/or bradycardia than those given DTPw alone.
Conclusion: When considering immunization for preterm infants, the benefits of early immunization must be balanced against the risk of apnoea and bradycardia. We recommend that the cardio-respiratory function of hospitalized infants born at less than 31 weeks gestation be monitored for 48 h post immunization. 相似文献
Methodology: A prospective study of 98 preterm infants, of gestational age 24–31 weeks, immunized at approximately 2 months post natal age with diphtheria-tetanus-whole cell pertussis vaccine (DTP
Results: Only one infant had apnoea and/or bradycardia pre-immunization compared with 17 post immunization. For 12 infants these events were brief, self-limiting and not associated with desaturations (oxygen saturation <90%). However, for five infants (30%) these events were associated with oxygen desaturation and two of these infants required supplemental oxygen. The group that had apnoea and/or bradycardia and the group that did not were not significantly different in terms of gestational age, birth weight and other variables. Infants who received Hib together with DTP
Conclusion: When considering immunization for preterm infants, the benefits of early immunization must be balanced against the risk of apnoea and bradycardia. We recommend that the cardio-respiratory function of hospitalized infants born at less than 31 weeks gestation be monitored for 48 h post immunization. 相似文献
54.
55.
Jennifer R. Charlton Yanzhe Xu Teresa Wu Kim A. deRonde Jillian L. Hughes Shourik Dutta Gavin T. Oxley Aleksandra Cwiek Helen P. Cathro Nathan P. Charlton Mark R. Conaway Edwin J. Baldelomar Neda Parvin Kevin M. Bennett 《Kidney international》2021,99(1):173-185
- Download : Download high-res image (366KB)
- Download : Download full-size image
56.
57.
Jennifer R. Charlton Caleb H. Springsteen J. Bryan Carmody 《Pediatric nephrology (Berlin, Germany)》2014,29(12):2299-2308
Although there is wide variation, humans possess on average 900,000 nephrons per kidney. So far as is known, nephrons cannot regenerate; therefore, an individual’s nephron endowment has profound implications in determining his or her long-term risk of developing chronic kidney disease. Most of the variability in human nephron number is determined early in life. Nephrogenesis is a complex and carefully orchestrated process that occurs during a narrow time window until 36 weeks gestation in humans, and disruption of any part of this sequence may lead to reduced nephron number. In utero, genetic abnormalities, toxic insults, and nutritional deficiencies can each alter final nephron number. Infants born prematurely must continue nephrogenesis in an ex utero environment where there may be multiple threats to successful nephrogenesis. Once the nephron endowment is determined, postnatal factors (such as acute kidney injury or chronic illnesses) can only decrease nephron number. Current techniques for estimating nephron number require an invasive procedure or complete destruction of the tissue, making noninvasive means for counting nephron surgently needed. A better understanding of nephron number and its determinants, particularly during growth and maturation, could allow the development of therapies to support, prolong, or resume nephrogenesis. 相似文献
58.
59.
60.